---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-26-000032"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:49:42.896572+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MacroGenics receives additional $60M from Sagard in amended ZYNYZ royalty deal

## Summary
- Received $60M cash from Sagard, bringing aggregate royalty purchase price to $130M.
- Eligible for up to $20M one-time milestone if ZYNYZ meets specified 2026 net sales thresholds.
- Royalty cap: Sagard gets 1.7x investment by Sep 30, 2032 or 2.0x thereafter; then rights revert.
- MacroGenics retains all other milestones and economic interests beyond the capped royalty.

## SEC filing metadata
- accession: 0001125345-26-000032
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534526000032/0001125345-26-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534526000032/mgnx-20260501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-26-000032
- JSON: https://secwatch.observer/filing/0001125345-26-000032.json
- Plain text: https://secwatch.observer/filing/0001125345-26-000032.txt

## Source-grounded claims
- claim_id: 48a1aab080812936fc0e3b3bb5df7f19a11e817e
  claim: MACROGENICS INC amended First Amendment to the Purchase and Sale Agreement with Sagard Healthcare Partners valued at $60.0 million additional cash payment, aggregate purchase price $130.0 million (effective 2026-05-01).
  evidence_excerpt: On May 1, 2026, MacroGenics, Inc. (the “Company”) and an entity affiliated with Sagard Healthcare Partners (“Sagard”) entered into a First Amendment (the “First Amendment”) to the Purchase and Sale Agreement, dated as of June 9, 2025 (the “Royalty Purchase Agreement”), pursuant to which the Company previously sold to Sagard its right to receive royalties on global net sales of ZYNYZ (retifanlimab-dlwr) under the Company’s Global Collaboration and License Agreement dated as of October 24, 2017, as amended (the “License Agreement”), with Incyte Corporation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1125345/000112534526000032/0001125345-26-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.